Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss” cash flows may end up underwriting the next act in the cancer war.
From Waistlines To War Rooms: Lilly’s GLP-1 Cash Machine
For Eli Lilly and Company (NYSE:LLY), the GLP-1 era is no longer a side hustle; it is the business model. GLP-1 drugs for diabetes and obesity have driven Lilly’s market capitalization past the 1 trillion dollar mark, making it the first healthcare company to join a club previously reserved for mega-cap tech. That kind of valuation gravity gives Lilly both a problem and an opportunity: it must convince investors this is not a one‑product story while using its new heft to quietly re-architect the rest of the pipeline.
Lilly has already signaled that strategy by plowing more than 3.5 billion dollars into a new Pennsylvania manufacturing facility focused on next-generation injectable weight-loss medicines like retatrutide, reinforcing its core GLP-1 franchise while it builds beyond it. At the same time, management has pointed to GLP-1 cash flows as the engine funding diversification into immunology, oncology, and genetic medicine, turning a weight-loss boom into a balance-sheet hedge against therapeutic concentration risk. In Wall Street terms, Lilly is using GLP-1s as its own internal private‑equity fund — with better margins and no carried interest.
The Quiet Radiopharma Land Grab
While GLP-1 headlines dominate financial television, the deal tape in radiopharmaceuticals reads like a quiet land rush. AstraZeneca plc (NASDAQ:AZN) stepped in with a roughly 2.4 billion dollar acquisition of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), paying a hefty premium to secure a platform built around targeted radiopharmaceutical oncology programs. Bristol Myers Squibb Company (NYSE:BMY) followed with a 4.1 billion dollar purchase of RayzeBio, Inc. (NASDAQ:RAYZ), whose lead asset RYZ-101 is in late‑stage development, underscoring big pharma’s willingness to pay up for differentiated radioligand assets.
Eli Lilly has hardly been a bystander. In addition to GLP-1 fuel, Lilly has deployed capital into the radiopharma ecosystem, including a 1.4 billion dollar deal for Point Biopharma Global Inc. (formerly NASDAQ:PNT) and collaboration agreements with Radionetics Oncology and Aktis Oncology, the latter involving upfront payments plus equity and an option to acquire. For investors, the pattern is clear: the same company that mastered metabolic disease with GLP-1s is quietly assembling exposure to radioactive precision oncology — a portfolio hedge that looks suspiciously like a secular theme.
NAYA Therapeutics: Targeted Alpha Therapy Moves From Theory To Pipeline
If big pharma is buying radiopharma at scale, emerging players like NAYA Therapeutics are where that story starts in the clinic. Based in South Florida and led by Founder and CEO Daniel Teper, NAYA is building a pipeline around two synergistic modalities: astatine‑211 targeted alpha therapies and NK‑engaging bifunctional antibodies, initially concentrating on hepatocellular carcinoma (HCC). The goal is to unlock deeper and more durable responses in patients who are not responding to today’s standard-of-care, positioning NAYA at the intersection of radiopharma and immune-oncology.
Targeted alpha therapies (TATs) use alpha‑emitting isotopes to deliver extremely potent radiation directly to tumor cells over a very short range — on the order of 50 to 100 micrometers — minimizing collateral damage to healthy tissue while packing enough punch that a single alpha hit can be lethal to a cancer cell. Astatine‑211, which has a 7.2‑hour half-life and can be produced from naturally abundant bismuth‑209, lends itself to reliable, cost-effective decentralized manufacturing, a design feature that matters when you are trying to scale precision therapies in real healthcare systems. NAYA’s NY‑703 program, a GPC3‑targeting Astatine‑211 TAT for hepatocellular carcinoma backed by a manufacturing partnership with Alpha Nuclide in China, exemplifies this thesis: pair a sharp biological target with a short‑range, high‑energy payload and build the supply chain moat from day one.
Inside Tribe Public’s “Can Targeted Alpha Therapy Cure Cancer?” Event
Last week, Tribe Public hosted its Next CEO Presentation and Q&A Webinar titled “Can Targeted Alpha Therapy Cure Cancer?” featuring NAYA Therapeutics’ Founder & CEO Daniel Teper, drawing investors, clinicians, and radiopharma watchers into the same virtual room. The discussion spotlighted how Astatine‑211–based TATs and bifunctional antibodies can be combined to go after solid tumors more aggressively, particularly in indications like hepatocellular carcinoma where relapse and residual disease remain stubbornly common. For an audience trained to parse GLP-1 prescription curves and obesity coverage debates, the shift to arc minutes and micrometers of alpha-particle range presented a different, but equally compelling, investment vocabulary.
What made the event notable was not just the science, but the capital markets subtext. As major acquirers like Eli Lilly (NYSE:LLY), AstraZeneca (NASDAQ:AZN), and Bristol Myers Squibb (NYSE:BMY) continue to pay rich multiples for radiopharma platforms such as Point Biopharma, Fusion Pharmaceuticals (NASDAQ:FUSN), and RayzeBio (NASDAQ:RAYZ), early-stage private companies like NAYA increasingly look like the upstream deal pipeline for the next wave of oncology M&A. Tribe Public’s format — a CEO‑level deep dive plus Q&A — gave investors an opportunity to interrogate not only the clinical rationale for TATs, but also the manufacturing, regulatory, and partnership strategies that could make NAYA a future target in this consolidating space.
Watch The Event Now
What Wall Street Is Really Hedging
The convergence of Lilly’s GLP‑1 boom, big pharma’s radiopharma buying spree, and NAYA’s alpha‑driven oncology ambitions suggests a deeper narrative: investors are no longer content with single‑modality stories, even when they are printing cash. GLP‑1 therapies have recalibrated expectations for what “blockbuster” means, but that same success is financing bets in areas like radiopharmaceuticals and targeted alpha therapy that may redefine long‑term growth beyond obesity and diabetes.
In that sense, Wall Street is hedging not against GLP‑1s, but against complacency. Companies like Eli Lilly (NYSE:LLY), AstraZeneca (NASDAQ:AZN), and Bristol Myers Squibb (NYSE:BMY) are treating radiopharma and TATs as strategic options on the future of oncology, while innovators like NAYA Therapeutics build the underlying science that will make those options valuable. For investors tracking both waistlines and tumor margins, the emerging theme is straightforward enough: follow the isotopes, and do not underestimate how far a GLP‑1 dollar can travel once it goes radioactive.
The Sources
- Eli Lilly Uses GLP-1 Strength To Build Broader Drug Pipeline – Yahoo Finance
https://finance.yahoo.com/news/eli-lilly-uses-glp-1-210630652.htmlfinance.yahoo - The 1 Trillion Dollar Drug Bet: How Eli Lilly Outsprinted Big Tech on Fat – Yahoo Finance
https://finance.yahoo.com/news/1-trillion-drug-bet-eli-174728500.htmlfinance.yahoo - Eli Lilly Expands Beyond GLP-1 With New Deals And Cancer Win – Yahoo Finance
https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-141202430.htmlfinance.yahoo - Eli Lilly soars past expectations to hit 45% sales growth in 2025 – Pharmaceutical Technology
https://www.pharmaceutical-technology.com/news/eli-lilly-soars-past-expectations-to-hit-45-sales-growth-in-2025/pharmaceutical-technology - Recap of Recent Radiopharmaceutical Deals – Maven Bio Blog
https://mavenbio.com/research/radiopharmaceutical-deals-recapmavenbio - As companies rush to radiopharmaceuticals for oncology, what’s next? – Fierce Pharma
https://www.fiercepharma.com/pharma/2025-forecast-companies-rush-radiopharmaceuticals-oncology-whats-nextfiercepharma - AstraZeneca joins radiopharmaceutical deals spree with 2.4 billion dollar Fusion buy – BioPharmaDive
https://www.biopharmadive.com/news/astrazeneca-fusion-acquire-radiopharmaceuticals/710651/biopharmadive - Targeted alpha anticancer therapies: update and future prospects – PMC (Journal article)
https://pmc.ncbi.nlm.nih.gov/articles/PMC4232037/pmc.ncbi.nlm.nih - Targeted Alpha Therapy – Orano Med
https://www.oranomed.com/en/targeted-alpha-therapyoranomed - Targeted alpha-particle therapy – Wikipedia
https://en.wikipedia.org/wiki/Targeted_alpha-particle_therapywikipedia - Medical applications of radionuclides and targeted Alpha Therapy – European Commission, JRC
https://joint-research-centre.ec.europa.eu/projects-and-activities/nuclear-science-base-standardisation-0/medical-applications-radionuclides-and-targeted-alpha-therapy_enjoint-research-centre.europa - New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer – News-Medical
https://www.news-medical.net/news/20251205/New-targeted-alpha-therapy-shows-promise-for-patients-radioiodine-refractory-thyroid-cancer.aspxnews-medical - Astatine-211 Targeted Alpha Therapies – NAYA Therapeutics
https://www.nayatx.com/astatine-211-targeted-alpha-therapiesnayatx - NAYA Therapeutics partners with Alpha Nuclide to advance Astatine-211 therapy for hepatocellular carcinoma – Medpath trial news
https://trial.medpath.com/news/e4c6693261bb40b5/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy-for-hepatocellular-carcinomatrial.medpath - BoB In South Florida: Daniel Teper, NAYA Therapeutics – Business of Biotech (podcast / transcript)
https://podcasts.apple.com/us/podcast/bob-in-south-florida-daniel-teper-naya-therapeutics/id1508008606?i=1000731581783podcasts.apple - BoB In South Florida: Daniel Teper, NAYA Therapeutics – YouTube episode
https://www.youtube.com/watch?v=dTs9N0j7hzoyoutube - Daniel Teper – Founder & CEO, NAYA Therapeutics (speaker bio)
https://targeted-radiopharma-target-selection-drug-design.com/speaker/daniel-teper/targeted-radiopharma-target-selection-drug-design - Targeted Alpha Therapy could be the next frontier in cancer treatment – CBC News
https://www.cbc.ca/news/health/cancer-treatment-research-targeted-alpha-therapy-1.7384434cbc - Targeted Alpha Therapy: Potent candidates for TAT – ScienceDirect (abstract)
https://www.sciencedirect.com/science/article/abs/pii/S0969805125000368sciencedirect - Killing cancer cells with alpha particles – explanatory overview (CBC)
https://www.cbc.ca/news/health/cancer-treatment-research-targeted-alpha-therapy-1.7384434cbc - Naya Therapeutics’ Founder & CEO, Daniel Teper – Tribe Public / YouTube CEO presentation
https://www.youtube.com/watch?v=XCtt3CedDA8youtube - Tribe Public – Company overview (platform hosting CEO & Q&A events)
https://pa.linkedin.com/company/tribe-publiclinkedin
